CYTO-202

CYTO-202 is an investigational **allogeneic natural killer cell immunotherapy** being developed by CytoImmune Therapeutics for **acute myeloid leukemia**. It is described by the company as a **FLT3-directed TRACK-CAR-NK cell therapy**, meaning an off-the-shelf engineered NK-cell product that uses a chimeric antigen receptor to recognize **FMS-like tyrosine kinase 3** on AML cells. CytoImmune's broader TRACK-NK platform is designed to combine direct tumor killing by engineered NK cells with immune stimulation through **soluble interleukin-15 secretion**; however, for CYTO-202 the publicly available information specifically identifies it as a FLT3-targeted CAR-NK program for AML and indicates a **preclinical** stage of development. Public details on commercial branding, final dosage form, and route of administration remain limited.

Other names

FLT3-directed TRACK-CAR-NK cell therapyFLT-3-directed TRACK-CAR-NK cell therapyFLT 3-directed TRACK-CAR-NK cell therapy